1. Globocan 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012. (Internet)
2. Siegel RL., Miller KD., Jemal A. Cancer statistics, 2015. // CA Cancer J Clin. - 2015. -V. 65, N 1. - P. 5-29.
3. Resnick KE., Hampel H., Fishel R.et al. Current and emerging trends in Lynch syndrome identification in women with endometrial cancer. // GynecolOncol. - 2009. - V. 114, N 1. - P. 128-34.
4. Van den Bosch T., Coosemans A., Morina M.et al. Screening for uterine tumours. // Best Pract Res ClinObstetGynaecol.- 2012. - V. 26, N 2. - P. 257- 66.
5. Dinkelspiel HE., Wright JD., Lewin SN.et al. Contemporary clinical management of endometrial cancer. // ObstetGynecol Int.- 2013. - V. 2013. - ID 583891.
6. Каприн А.Д., Старинский В.В., Петрова Г.В. Злокачественные новообразования в России в 2016 г. (заболеваемость и смертность) // М.: МНИОИ им. П.А.Герцена -филиал ФГБУ «НМИЦ радиологии» Минздрава России, - 2018. - 250 с.
7. Бохман Я.В. Руководство по онкогинекологии. — М.: Медицина, 1989. — 325 с.
8. Kurman RJ.,Carcangiu ML., Harrington CS., Young RH, eds. WHO Classification of Tumors of the Female Reproductive Organs. Geneva, Switzerland: WHO Press; 2014. World Health Organization Classification of Tumors. 4th edition.
9. FIGO Committee on Gynecologic Oncology. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium.// Int J Gynecol Obstet. - 2009. - V. 105, N 2. - P. 1034.
10. Amanta F., Mirzab M., Creutzbergc C. FIGO cancer report 2012. Cancer of the corpus uteri. // Int J Gynecol Obstet. - 2012. - V. 119, S 2. - P. S110-S117.
11. Cade TJ., Quinn MA., McNally OM. et al. Predictive value of magnetic resonance imaging in assessing myometrial invasion in endometrial cancer: is radiological staging sufficient for planning conservative treatment? Int J Gynecol Cancer. - 2010. - V. 20, N 7. - P. 1166-9.
12. Ortashi O, Jain S, Emannuel O. et al. Evaluation of the sensitivity, specificity, positive and negative predictive values of preoperative magnetic resonance imaging for staging endometrial cancer. A prospective study of 100 cases at the Dorset Cancer Centre. // Eur J ObstetGynecolReprod Biol. 2008 Apr;137(2):232-5.
13. Kitajima K, Suzuki K, Senda M, et al. Preoperative nodal staging of uterine cancer: is contrast-enhanced PET/CT more accurate than non-enhanced PET/CT or enhanced CT alone? // Ann Nucl Med. 2011 Aug;25(7):511-9.
14. Antonsen SL, Jensen LN, Loft A, et al. MRI, PET/CT and ultrasound in the preoperative staging of endometrial cancer - a multicenter prospective comparative study. // GynecolOncol. 2013 Feb;128(2):300-8.
15. Kwon JS, Scott JL, Gilks CB, et al. Testing women with endometrial cancer to detect Lynch syndrome. // J ClinOncol. 2011 Jun 1;29(16):2247-52.
16. Crispens MA. Endometrial and ovarian cancer in lynch syndrome. // Clin Colon Rectal Surg. 2012 Jun;25(2):97-102.
17. Walker JL, Piedmonte MR, Spirtos NM, et al. Recurrence and survival after random assignment to laparoscopy versus laparotomy for comprehensive surgical staging of uterine cancer: Gynecologic Oncology Group LAP2 Study. // J ClinOncol. 2012 Mar 1;30(7):695-700
18. Mourits MJ, Bijen CB, Arts HJ, et al. Safety of laparoscopy versus laparotomy in early-stage endometrial cancer: a randomised trial. // Lancet Oncol. 2010 Aug;11(8):763-71.
19. Wang HL, Ren YF, Yang J, et al. Total laparoscopic hysterectomy versus total abdominal hysterectomy for endometrial cancer: a meta-analysis. // Asian Pac J Cancer Prev. 2013;14(4):2515-9.
20. Krill LS, Bristow RE. Robotic surgery: gynecologic oncology. // Cancer J. 2013 Mar-Apr;19(2):167-76.
21. ACOG practice bulletin, clinical management guidelines for obstetrician-gynecologists, number 65, August 2005: management of endometrial cancer. // Obstet Gynecol. 2005 Aug;106(2):413-25.
22. Wright JD, Buck AM, Shah M, et al. Safety of ovarian preservation in premenopausal women with endometrial cancer. // J ClinOncol. 2009 Mar 10;27(8):1214-9.
23. Koskas M, Bendifallah S, Luton D, et al. Safety of uterine and/or ovarian preservation in young women with grade 1 intramucous endometrial adenocarcinoma: a comparison of survival according to the extent of surgery. // FertilSteril. 2012 Nov;98(5):1229-35.
24. Lee TS, Lee JY, Kim JW, et al. Outcomes of ovarian preservation in a cohort of premenopausal women with early-stage endometrial cancer: a Korean Gynecologic Oncology Group study. // GynecolOncol. 2013 Nov;131(2):289-93.
25. Fishman DA, Roberts KB, Chambers JT, et al. Radiation therapy as exclusive treatment for medically inoperable patients with stage I and II endometrioid carcinoma with endometrium. // GynecolOncol. 1996 May;61(2):189-96.
26. Coon D, Beriwal S, Heron DE, et al. High-dose-rate Rotte "Y" applicator brachytherapy for definitive treatment of medically inoperable endometrial cancer: 10-year results. // Int J RadiatOncolBiol Phys. 2008 Jul 1;71(3):779-83.
27. Niazi TM, Souhami L, Portelance L, et al. Long-term results of high-dose-rate brachytherapy in the primary treatment of medically inoperable stage I-II endometrial carcinoma. // Int J RadiatOncolBiol Phys. 2005 Nov 15;63(4):1108-13.
28. Gunderson CC, Fader AN, Carson KA, et al. Oncologic and reproductive outcomes with progestin therapy in women with endometrial hyperplasia and grade 1 adenocarcinoma: a systematic review. // GynecolOncol. 2012 May;125(2):477-82.
29. Baker J, Obermair A, Gebski V, et al. Efficacy of oral or intrauterine device-delivered progestin in patients with complex endometrial hyperplasia with atypia or early endometrial adenocarcinoma: a meta-analysis and systematic review of the literature. // GynecolOncol. 2012 Apr;125(1):263-70.
30. Colombo N., Creutzberg C., Amant F. et al. ESMO-ESGO-ESTRO Consensus conference on endometrial cancer. Diagnosis, treatment and follow-up. // Int J Gynecol Cancer. - 2016. - V. 26, N 1. - P. 2-30.